1. PARPi combinations against HR-proficient tumors.
PARPi combinations against HR-proficient tumors. Rationale behind use of specific PARPi combinations as a strategy against HR-proficient tumors. Specifically, use of agents that inhibit HR, such as CDK1 or HSP90 inhibitors may render HR-proficient tumors into HR-deficient tumors and thus sensitize them to platinum or PARPis. The proposed mechanism of HR suppression and the clinical status of these PARPi combinations are presented in the right panel.
Panagiotis A. Konstantinopoulos et al. Cancer Discov 2015;5:
©2015 by American Association for Cancer Research